Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles can cross the blood–brain barrier (BBB), but little is known about passage. Here, we used multiple-time regression analysis to examine the ability of 10 exosome populations derived from mouse, human, cancerous, and non-cancerous cell lines to cross the BBB. All crossed the BBB, but rates varied over 10-fold. Lipopolysaccharide (LPS), an activator of the innate immune system, enhanced uptake independently of BBB disruption for six exosomes and decreased uptake for one. Wheatgerm agglutinin (WGA) modulated transport of five exosome populations, suggesting passage by adsorptive transcytosis. Mannose 6-phosphate inhibited uptake of J774A.1, demonstrating that its BBB transporter is the mannose 6-phosphate receptor. Uptake rates, patterns, and effects of LPS or WGA were not predicted by exosome source (mouse vs. human) or cancer status of the cell lines. The cell surface proteins CD46, AVβ6, AVβ3, and ICAM-1 were variably expressed but not predictive of transport rate nor responses to LPS or WGA. A brain-to-blood efflux mechanism variably affected CNS retention and explains how CNS-derived exosomes enter blood. In summary, all exosomes tested here readily crossed the BBB, but at varying rates and by a variety of vesicular-mediated mechanisms involving specific transporters, adsorptive transcytosis, and a brain-to-blood efflux system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 On-bead flow cytometry of exosome populations isolated from supernatants of 4 different cell lines, captured on streptavidin beads coated with biotinylated anti-CD63 mAbs and stained with the labeled detection Abs specific for CD46, αVβ6, αVβ3 and ICAM1 as described in Methods. Data are relative fluorescence intensity (RFI) values calculated as mean fluorescence intensity (MFI) of an experimental sample/MFI of an isotype control Ab. [White peaks = experimental samples; hatched peaks = isotope controls]. Note that exosomes produced by non-malignant cells (HaCaT and primary T cells) appear to differ from exosomes produced by malignant cells by the absence of αVβ3 and lower expression levels of αVβ6. Representative results are from 1 to 3 detection experiments performed with each exosome population.](https://figures.cochat.ai/paper-figures/624d7ee716904379955ce30fbf39b5dc/transport-of-extracellular-vesicles-across-the-blood-brain-barrier-brain-figure-2.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, EVs have inherent targeting capabilities and can cross the BBB, facilitating efficient delivery of therapeutic cargo to the CNS [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain-derived EVs have been found to harbor the ability to penetrate the BBB. This breakdown is crucial as it potentially allows for releasing these EVs into peripheral circulation [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“sEVs can cross the blood–brain barrier and deliver cargo with crucial roles in many neurological disorders [17–23].”
From Differential RNA packaging into small extracellular vesicles by neurons and astrocytes (2021) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 3×
“EVs we refer to as “exosomes” were isolated by mini-size exclusion chromatography (SEC) from supernatants of 10 different human or murine cell lines (Table 1) and characterized according to the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) criteria [2], as is routinely done in our laborato…”
BackgroundMethodShedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369 · cited 2×
“of parent cells, where they are formed by inverse membrane invagination as intraluminal vesicles inside multivesicular bodies (MVBs) [4].”
BackgroundExtracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“Exosomes are a subset of small extracellular vesicles (EVs) that are produced by all normal and malignant cells and are present in all body fluids [1].”
BackgroundGraphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009 · cited 1×
“, drug-loaded exosomes enter the brain using the same mechanisms as those employed by the parent cells [12].”
BackgroundAbels, E. R., & Breakefield, X. O. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0366-z · Cited by 1,678 · cited 1×
“Among the various EVs, exosomes are sized at 30–150 nm in diameter and are of special interest because of their origin, their ability to freely circulate and infiltrate various tissues and their molecular content mirroring that of parental cells [3].”
BackgroundZhang, H., Freitas, D., Kim, H. S., Fabijanic, K., Li, Z., Chen, H., Mark, M. T., Molina, H., Martin, A. B., Bojmar, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0040-4 · Cited by 1,613 · cited 1×
“The orientation of surface proteins in exosome membranes resembles that in the cell membrane of parent cells [5].”
BackgroundExtracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,429 · cited 2×
“Exosomes serve as an intercellular communication system, shuttling messages between cells and also conveying peptides, proteins, and genetic materials from parental to recipient cells [6].”
BackgroundFrom blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citation
Research works printed but not linked: 1
- Nicolini, M., and Zatta, P.F. (1994). Glycoconjugates and anionic sites in the blood-brain barrier. Glycobiology and the Brain, Pergamon Press.
Cited by
Items 301–400 of 569
Yeo, H. R., Kim, Y. J., Seok, J., Kwak, Y., Jang, S. B., Lim, N. H., Song, K., Lee, J., Cho, M., Kim, S. W., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02033-9 · Cited by 13
Extracellular vesicle-mediated mitochondria delivery: Premise and promise
Manickam, D. S., Pinky, P. P., & Khare, P. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251349304 · Cited by 13
“86 These studies are currently underway in our laboratory to support the further development of m/ lEVs as a delivery carrier for mitochondria in preclinical models of stroke.”
Gao, Y., Tang, S., Liu, J., Yang, X., Chen, H., Li, J., & Ni, X. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70483 · Cited by 11
“Previous studies have confirmed that circulating EVs can interact between the brain and circulatory system and transmit peripheral information to the brain [24].”
de Rezende, V. L., Mathias, K., da Costa, M. D. A., Gonçalves, C. L., Barichello, T., & Petronilho, F. C. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70155 · Cited by 9
Togre, N. S., Bhoj, P. S., Mekala, N. K., Hancock, R., Trivedi, J., & Persidsky, Y. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106115 · Cited by 8
“These EV cargoes act on BBB endothelium via multiple routes as described below (Schnatz et al., 2021; de la Monte et al., 2009; Murphy et al., 2019; Banks et al., 2020b).”
Hong, C.-E., & Lyu, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101258 · Cited by 17
Salim, M. W., Zhang, W., Collins‐Praino, L. E., Wang, Y., & Care, A. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504608 · Cited by 8
Calderazzo, S. M., Covert, M., de Alba, D., Bowley, B. G. E., Pessina, M. A., Rosene, D. L., Buller, B., Medalla, M., & Moore, T. L. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.08.001 · Cited by 11
“trate the blood brain barrier (Matsumoto et al., 2017; Banks et al., 2020) and appear to promote functional recovery, anti-inflammatory responses, and plasticity in rodent models (Katakowski et al.”
BackgroundCadoret, A., Dion‐Albert, L., Amrani, S., Caron, L., Théberge, M., Turmel, A., Lebel, M., & Ménard, C. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114443 · Cited by 9
Identification of blood exosomal metabolomic profiling for high-altitude cerebral edema
Tang, Q., Fan, F., Chen, L., Chen, Y., Yuan, L., Wang, L., Xu, H. Y., Zhang, Y., & Cheng, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-62360-0 · Cited by 7
Afshar, Y., Sharifi, N., Kamroo, A., Yazdanpanah, N., Saleki, K., & Rezaei, N. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0095 · Cited by 10
Burrows, K., Figueroa‐Hall, L. K., Kuplicki, R., Stewart, J. L., Alarbi, A. M., Ramesh, R., Savitz, J. B., Teague, T. K., Risbrough, V. B., & Paulus, M. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-04875-y · Cited by 9
A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders
Hegeman, C. V., de Jong, O. G., & Lorenowicz, M. J. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.41 · Cited by 9
Harrison, M. S., Driscoll, B. G., Farnsworth, J., Hinton, A. S., Peppi, M., McLean, W., & Parham, K. (2023) · Otology and Neurotology · doi:10.1097/mao.0000000000003994 · Cited by 7
Shishido, S. N., Marvit, A., Pham, D., Luo, T., Xu, L., Mason, J. M., Priceman, S. J., Portnow, J., & Kühn, P. (2024) · Cancers · doi:10.3390/cancers16223746 · Cited by 8
Incorporation of recombinant proteins into extracellular vesicles by Lactococcus cremoris
Plavec, T. V., Soderžnik, K. Ž., Pelle, G. D., Zupančič, Š., Vidmar, R., & Berlec, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-86492-z · Cited by 8
Derisfard, F., Jafarinezhad, Z., Azarpira, N., Namavar, M. R., & Aligholi, H. (2025) · Neuroreport · doi:10.1097/wnr.0000000000002133 · Cited by 7
“Furthermore, the ability of exosome to cross the BBB efficiently makes it a friendly potential treatment in neurological diseases [15,16].”
Pisoni, L., Donini, L., Gagni, P., Pennuto, M., Ratti, A., Verde, F., Ticozzi, N., Mandrioli, J., Calvo, A., & Basso, M. (2025) · Cells · doi:10.3390/cells14110848 · Cited by 8
“A 10-fold variation rate was reported among cell lines, suggesting that specific surface proteins may favor EV uptake in the CNS [142].”
InfluentialLedreux, A., Carmona‐Iragui, M., Videla, L., Benejam, B., Barroeta, I., Lleó, A., Alcolea, D. A., & Fortea, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70380 · Cited by 7
Zhang, C., Liu, Y., Bai, T., Shao, H., Xiong, Z., Epstein, M. M., Li, X., & Chen, H. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108637 · Cited by 9
Hu, J., Shi, M., Tian, M., Xie, B., Tan, Y., Zhou, D., Qian, T., & Qin, D. (2026) · Pharmaceuticals · doi:10.3390/ph19010094 · Cited by 10
Villena-Rueda, B. E., Kajitani, G. S., Ota, V., Mauer, J., Santoro, M. L., Bugiga, A., Rosa, J. S., Asprino, P. F., Meneghetti, P., Torrecilhas, A. C., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04194-5 · Cited by 9
Rasouli, A., Roshangar, L., Hosseini, M., Pourmohammadfazel, A., & Nikzad, S. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.06.031 · Cited by 7
Alehossein, P., Taheri, M., Ghahremani, P. T., Dakhlallah, D. A., Brown, C. M., Ishrat, T., & Nasoohi, S. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01025-4 · Cited by 8
“That is, five weeks of AIT and MCT decreased the percentages of TF expressing EVs, following stimulating HETneutrophil-rich samples by LPS (Lipopolysaccharide) or PMA (a protein kinase C activator) [49].”
BackgroundMethodInfluentialNeuroprotective Effects of Astrocyte Extracellular Vesicles in Stroke
Yakovlev, A. A. (2022) · Neurochemical Journal · doi:10.1134/s1819712422020143 · Cited by 7
Elsworthy, R. J., Dunleavy, C., Whitham, M., & Aldred, S. (2022) · Aging and Health Research · doi:10.1016/j.ahr.2022.100093 · Cited by 9
Chen, H., Xu, H., Zhang, W., Luo, Z.-Y., Zhang, Z., Shi, H.-H., Dong, Y.-C., Xie, Z., Ben, Y., & An, S. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x301827240613063513 · Cited by 8
Mirzaahmadi, B., Ahmadian, S., Haddadi, P., Nezhad‐Mokhtari, P., Nezamdoust, F. V., Yalameha, B., Chegeni, S. A., Rashidi, S., Mousakhani, A., Sokullu, E., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02286-w · Cited by 11
“Exos primarily use transcytosis to cross the BBB via engaging specific glycoproteins, which are recruited after the stimulation of EC receptors [70].”
Saba, E. S., Mrad, M. F., Nakib, L., Dermesrobian, V., Abboud, J., & Khoury, S. J. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03567-4 · Cited by 7
Ray, S., Kumar, M., Chemparathy, D. T., Dash, P. K., & Sil, S. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70191 · Cited by 7
Extracellular Vesicles and Extracellular RNAs in Plant–Microbe Interactions
Koch, B. L., Singla‐Rastogi, M., & Innes, R. W. (2026) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-063025-110704 · Cited by 9
Saviana, M., Romano, G., Morales, D. D. V., Acunzo, M., & Nana-Sinkam, P. S. (2026) · Comprehensive physiology · doi:10.1002/cph4.70128 · Cited by 8
“Also, EV populations derived from mice, human, cancerous, and non-cancerous cell lines can bidirectionally cross the BBB at different rates (Banks et al. 2020).”
Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Khan, I., Gril, B., Paranjape, A. N., Robinson, C. M., Difilippantonio, S., Biernat, W., Bieńkowski, M., Pęksa, R., Duchnowska, R., Jassem, J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0815 · Cited by 7
Xiang, X., Pan, X., Lv, W., Chen, S., Li, J., Zhang, H., Liao, Y., Yu, J., Li, J., Dang, Y., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1488 · Cited by 6
Keysberg, C., Hertel, O., Hoffrogge, R., Reich, S., Hornung, N., Holzmann, K., & Otte, K. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28612 · Cited by 8
“Finally, they are able to cross the blood – brain ‐ barrier (Banks et al., 2020), and since targeted and tolerable drug delivery to specific cells or tissues is one of the biggest challenges for drug application today, therapeutic sEVs seem an apt or, in some cases, only solution for this.”
BackgroundAdvances in exosome modulation of ferroptosis for the treatment of orthopedic diseases
Cui, H., Wang, Y., Ma, J., Zhou, L., Li, G., Li, Y., Sun, Y., Shen, J., Ma, T., Wang, Q., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155312 · Cited by 6
Cicuéndez, I. D.-M., Castro‐Robles, B., Villar, M., García‐García, J., Martín, Ó. A., Serrano‐Heras, G., & Segura, T. (2024) · Translational Stroke Research · doi:10.1007/s12975-024-01283-4 · Cited by 9
Kögel, D., Temme, A., & Aigner, A. M. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108762 · Cited by 7
Kovács, O. T., Soltész‐Katona, E., Marton, N., Baricza, E., Hunyady, L., Turu, G., & Nagy, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084221 · Cited by 6
iTRAQ-Based Proteomic Analysis of APP Transgenic Mouse Urine Exosomes
Zhou, X., Sheikh, A. M., Matsumoto, K., Mitaki, S., Shibly, A. Z., Zhang, Y., Garu, A., Yano, S., & Nagai, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010672 · Cited by 8
Extracellular Vesicles: A New Approach to Study the Brain’s Neural System and Its Diseases
Afridi, S., Sharma, P., Choudhary, F., Rizwan, A., Nizam, A., Parvez, A., & Farooqi, H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01271-3 · Cited by 6
“It was reported that CD46 is a major BBB receptors mediating the vesicular transport of normal and cancerous cell-derived EVs [25, 26].”
Self-citationAppropriate antibiotic prescribing for the general dentist.
Goodchild, J. H., & Donaldson, M. (2009) · PubMed · Cited by 6
Editorial: Advances in brain tumors diagnosis and treatment
de Biase, D., Franceschi, E., & Marucci, G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1152547 · Cited by 6
“However, it has been shown that exosomes microvesicles and apoptotic vesicles can all cross the intact BBB, and then peripheral blood may be sometimes used for analysis of circulating markers in glioma (10).”
BackgroundExosomes in Metabolic Diseases: From Molecular Mechanisms to Clinical Applications
Wu, Y., Yang, S., Zhang, Y., & Su, Z. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70031 · Cited by 5
Tarasova, K. V., Arteaga, M. B., Kidtiwong, A., Nivarthi, H., Gamauf, J., Corso, G., Gültekin, S., Bileck, A., Rothbauer, M., Toegel, S., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04585-y · Cited by 6
Allogeneic Treg-derived artificial vesicles: A promising therapeutic modality for multiple sclerosis
Ganeeva, I., Gilyazova, E., Khannanov, A., Nektorova, M. E., Rogov, A. M., Хайбуллин, Т. И., Zmievskaya, E., & Bulatov, E. (2025) · Bioimpacts · doi:10.34172/bi.30880 · Cited by 5
Intranasal delivery systems for traumatic brain injury: Advancements and perspectives
Yoo, S. H., Heo, S. C., Bae, J. S., Lee, J. H., Knowles, J. C., & Kim, H. (2025) · Journal of Tissue Engineering · doi:10.1177/20417314251372373 · Cited by 7
“195 Exosomes can cross the BBB and are extensively used as drug carriers, 196–198 suggesting that intranasal exosome therapy might mitigate harmful neuroinflammatory processes.”
Arnold, P., Boros, F. A., Mattner, J., Seidel, G., Liu, C., Hensel, I. V., Deun, J. V., Schwendner, R., Müller‐Deile, J., Sopel, N., et al. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70093 · Cited by 8
“…the origin of the vesicles and pathophysiological changes such as inflammation, are also strong determinants of the ability of EVs to cross the BBB. Banks et al. (2020) investigated the effect of the cellular origin on the efficiency of exosome transport through the BBB by assessing the transport…”
Redefining the Limits of Nanodevices-Based Drug Delivery Systems: Extracellular Vesicles
Díaz, M. L., Simón, V., Benedini, L. A., & Messina, P. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121617 · Cited by 6
“These processes protect the active agents from degradation active agents from the environment and their incorporation, depending on their physicochemical and degradative behavior, is carried out by different engineered approaches to optimize their intended properties [18].”
Holghoomi, R., Rahdar, A., Kadkhoda, J., Mohammadzadeh, V., Shirzad, M., Salehi, B., Ebrahimi, M.-S., & Pandey, S. (2026) · Nano LIFE · doi:10.1142/s179398442630013x · Cited by 6
Wu, X., Sun, Z., Wang, Y.-E., Shen, X., Tao, L., Shen, X., Sun, X., & Wu, G. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.163186 · Cited by 5
Askenase, P. W. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.987117 · Cited by 5
“Then, as physiologic, they have the ability to traverse the epithelial and endothelial cells of the BBB by undergoing transcytosis (Banks et al., 2020; Saint-Pol et al., 2020).”
BackgroundExtracellular Vesicles: The Invisible Heroes and Villains of COVID‐19 Central Neuropathology
Chang, H., Chen, E., Hu, Y., Wu, L., Deng, L., Ye, S., Mao, X., Zhu, T., Liu, J., & Chen, C. (2023) · Advanced Science · doi:10.1002/advs.202305554 · Cited by 4
HIV Tat as a latency reversing agent: turning the tables on viral persistence
Fisher, B. M., Cevaal, P. M., Roche, M., & Lewin, S. R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571151 · Cited by 10
Sanchez, B. C., Hinchliffe, M., Ellis, M., Simpson, C., Humphreys, D. P., Sweeney, B., & Bracewell, D. G. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28776 · Cited by 4
“The capacity for EVs to shuttle complex cargo across biological barriers, including the blood – brain barrier (Banks et al., 2020), has led to immense interest over the past 15years to harness EVs as a potential class of delivery system (Roy et al., 2018).”
Nef is a key player in neuroinflammation and myelin impairment associated with neuroHIV
Bukrinsky, M. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1553594 · Cited by 5
Unveiling Exosome Potential: Transforming Treatments for Neurodegeneration
Tiwari, A. K., Singh, B. K., Singh, G. K., Meena, J., Agrawal, A. K., Kumar, S., & Modi, G. P. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00096 · Cited by 6
Citron, B. A., Guzman, M., Shapdoor, B., Rameshwar, P., Sokratian, A., Shaikh, A. L., Mausoof, A. E., West, A. B., & Delic, V. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70084 · Cited by 5
Mitsuhashi, M., Epps, D. V., Sun, H., Xing, L., Kawata, K., Jiménez, V., Williams, V. B., Sasannejad, C., James, M. L., Edwardson, M. A., et al. (2025) · Cells · doi:10.3390/cells14221771 · Cited by 4
“EVs are secreted into the interstitial fluid, diffuse through extracellular matrix, and enter the bloodstream primarily via transendothelial transport [26] or lymphatic drainage [27].”
Khare, P., Edgecomb, S. X., Hamadani, C. M., Hu, D., Govindaswamy, B., Taylor, G. R., Caprara, R., Tanner, E. E. L., & Manickam, D. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114487 · Cited by 6
Exercise-induced plasma-derived extracellular vesicles increase adult hippocampal neurogenesis
Connolly, M. G., Fliflet, A. M., Ravi, P., Rosu, D. I., Boppart, M. D., & Rhodes, J. S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150003 · Cited by 5
Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration
Lü, K., & Koziol, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010320 · Cited by 6
“…EVs, and BBB-on-chip live imaging to directly visualize transcytosis, show that peripheral small EVs cross the BBB and distribute within brain parenchyma and vasculature, and conversely, brain-derived EVs can be detected in the circulation after crossing endothelial barriers [53,162,163].”
Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy
Chelvaretnam, S., Mom, K. T., Palma, C., Pham, Q., Fitri, A., Bhuiyan, S., Shojaee, M., Asari, K., Rashid, H., Hinch, L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052163 · Cited by 5
Sun, Y., Xu, Z., Cui, L., Guo, J., Zhang, X., & Xiao, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s608292 · Cited by 7
COVID‐19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks
Zhong, C., Cohen, K., Lin, X., Schiller, E. A., Sharma, S., & Hanna, N. N. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13934 · Cited by 5
“S protein has been hypothesized to have a role in the pathogenesis of Long-COVID [56–59] and long-term post-COVID vaccine injury [60, 61].”
Ghosal, S., Bodnár, B. R., Kestecher, B. M., Nagy, Á., László, T., Yilmaz, B., Zeng, Y., Szabó, A., Bödör, C., Buzás, E. I., et al. (2025) · Current Opinion in Physiology · doi:10.1016/j.cophys.2025.100815 · Cited by 7
Feix, A. S., Tabaie, E. Z., Singh, A. N., Wittenberg, N. J., Wilson, E. H., & Joachim, A. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00037-24 · Cited by 8
“Moreover, EVs have a low immunogenicity and capacity to traverse the blood–brain barrier, further enhanc ing their suitability for drug delivery applications (27, 167).”
BackgroundShuler, K. T., Rodríguez, J. L., Levy-Myers, R., & Sockanathan, S. (2024) · Cells · doi:10.3390/cells13171414 · Cited by 5
FMR1 Disorders: Basics of Biology and Therapeutics in Development
Gillett, D. A., Tigro, H., Wang, Y., & Suo, Z. (2024) · Cells · doi:10.3390/cells13242100 · Cited by 6
Zagrodnik, J. L., Blandford, S. N., Fudge, N. J., Arsenault, S. T., Anthony, S., McGrath, L., Clift, F., Stefanelli, M., & Moore, C. S. (2025) · Clinical & Experimental Immunology · doi:10.1093/cei/uxaf003 · Cited by 4
“As EVs readily cross the BBB [33], we postulate that CD3 + EVs may indeed be migrating into the CNS and potentially contributing to a pathophysiology that manifests in worsening disability.”
Kulakauskienė, D., Narauskaitė, D., Gečys, D., Juknaitė, O., Jankauskaitė, L., Masaitytė, A., Šventoraitienė, J., Inokaitis, H., Miknienė, Z., Sadauskienė, I., et al. (2021) · Biology · doi:10.3390/biology10121359 · Cited by 6
“Interferons alpha and gamma belong to different interferon groups, and both are known to activate the NFkappaB pathway, which stimulates CCL5, IL-1β and TNF-α [63,64].”
InfluentialShamshiripour, P., Rahnama, M., Nikoobakht, M., Hajiahmadi, F., Moradi, A., & Ahmadvand, D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1292083 · Cited by 4
Engineered retrovirus-like nanocarriers for messenger RNA delivery into neuronsPreprint
Gu, W., Luozhong, S., Cai, S., Londhe, K., Elkasri, N., Hawkins, R. D., Yuan, Z., Greene, K. S., Cruz, M., Chang, Y.-W., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.07.518870 · Cited by 4
Rosina, M., Scaricamazza, S., Riggio, F., Fenili, G., Giannessi, F., Matteocci, A., Nesci, V., Salvatori, I., Angelini, D. F., Aquilano, K., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41801 · Cited by 3
“The importance of studying EVs in ALS pathology is based on the fact that these vesicles are able to cross the blood brain barrier [84].”
Balic, N., Perković, M. N., Milos, T., Vuić, B., Kodzoman, M. K., Štrac, D. Š., & Erjavec, G. N. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111393 · Cited by 4
Xavier, G., Ota, V., Kajitani, G. S., Mauer, J., Asprino, P. F., Costa, G. O., Cavalcante, D. A., Cerqueira, R. O., Novaes, A., dos Santos, F. R., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.10.011 · Cited by 5
Lukacher, A. S., Yuan, W., O’Hara, B. A., Garabian, K., Haley, S. A., & Atwood, W. J. (2025) · Tumour Virus Research · doi:10.1016/j.tvr.2025.200331 · Cited by 3
“EVs have been shown to cross the BBB intact in vitro and in vivo via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis [106 – 109].”
Zheng, Y., Jurgielewicz, B. J., Helton, L. G., Rideout, H. J., Kennedy, E. J., Stice, S., & Yao, Y. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70116 · Cited by 3
“This process occurs through diverse mechanisms (Banks et al. 2020 , Saint-Pol et al. 2020 ), such as transcytosis, endocytosis, membrane fusion, ligand-mediated targeting to the BBB or neurons, or other unknown pathways.”
Extracellular vesicle therapeutics in Alzheimer’s disease: mechanisms, progress, and prospects
Fang, Y., Hao, X., & Fang, B. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.158 · Cited by 3
From Lipids to Mitochondria: Shared Metabolic Alterations in Obesity and Alzheimer’s Disease
Uranga, R. M., & Allani, S. K. (2026) · Cells · doi:10.3390/cells15080672 · Cited by 3
“Notably, EVs have been reported to traverse multiple brain barriers, including the BBB, the blood–CSF barrier, and the ependyma [60].”
Lu, X., Jiang, Y., Lin, X., Zhang, Y. X., Liu, Q., & Chen, S. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03866-4 · Cited by 3
“Crucially, SEVs possess the intrinsic ability to traverse biological barriers, including the BBB, facilitating the direct delivery of bioactive cargo to the central nervous system [13, 14].”
Plant-derived extracellular vesicles for drug delivery: current and future
Xu, F., Liu, Y. H., Zhang, Q., Tang, R., Li, H., Yang, H., & Lin, L. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag109 · Cited by 5
“ADEVs universally cross the BBB, yet their transport rates and underlying mechanisms are highly heterogeneous [167].”
The potential of bioengineered exosomes in regenerative medicine: a next generation therapy
Kumari, S., Agnihotri, A., Sharma, A., Dongre, S., Tiwari, A., Soni, N., & Bissa, B. (2026) · Human Cell · doi:10.1007/s13577-026-01400-5 · Cited by 3
Liu, S. X., Calderon, D. G. V., Maxim, Z. L., Beeson, M. M., Rao, R., & Tran, P. V. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.03.014 · Cited by 4
Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?
Dubey, A. R., Patwa, S. M., Kinger, S., Jagtap, Y. A., Kumar, P., Singh, S., Dhiman, R., Jha, H. C., & Mishra, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02775-w · Cited by 4
“Concerns about the hindrance for biomarker in crossing BBB are also mentioned.”
BackgroundInfluentialThe Role of Mesenchymal Stromal Cells and Their Products in the Treatment of Injured Spinal Cords
Slovinská, L., & Harvanová, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060329 · Cited by 3
Nonenzymatic properties of ureases
Grahl, M. V. C., Uberti, A. F., & Carlini, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91800-8.00013-8 · Cited by 5
3′-UTR Sequence of Exosomal NANOGP8 DNA as an Extracellular Vesicle-Localization Signal
Vaidya, M., Kimura, A., Bajaj, A., & Sugaya, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137294 · Cited by 4
Koutroulis, I., Kratimenos, P., Hoptay, C. E., O'Brien, W. N., Sanidas, G., Byrd, C. E., Triantafyllou, M., Goldstein, E. Z., Jablonska, B., Bharadwaj, M. S., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110573 · Cited by 4
Nanomedicines for Delivery Across the Blood–Brain Barrier
Lalatsa, A., Das, D., & Osouli-Bostanabad, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-59478-6_11 · Cited by 2
Ghosh, S., Choudhury, S. H., Mukherjee, K., & Bhattacharyya, S. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_16 · Cited by 5
Effect of Kinases in Extracellular Vesicles from HIV-1-Infected Cells on Bystander Cells
Mensah, G. A., Williams, A., Khatkar, P., Kim, Y., Erickson, J. W., Duverger, A. E., Branscome, H., Patil, K., Chaudhry, H., Wu, Y., et al. (2025) · Cells · doi:10.3390/cells14020119 · Cited by 2
“Unlike cART, exosomes have been shown to cross the blood–brain barrier and stimulate brain cells including microglia—the main HIV-1 reservoir in the brain [59,60].”
Zhang, Y., Lv, Y., Wang, Y., Fu, W., Shi, X.-Y., Liu, J., Wen, J., Li, X., & Li, B. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107312 · Cited by 3
Rossi, R., Cano, A. C., Pallarès-Rusiñol, A., Ruiz, A., Martí, M., & Pividori, M. I. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.118061 · Cited by 5
Xu, M., Wang, H., Wang, C., Wang, C., Hu, S., & Weng, L. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126221 · Cited by 2
Unlocking extracellular mitochondria from bench to clinical application in stroke
Hamanaka, G., Back, D.-B., Park, J.-H., Ishikane, S., & Hayakawa, K. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf060 · Cited by 2
Wang, X., Fan, Y., Dong, X., Wu, H., & Guan, Q. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112152 · Cited by 4
RNA transcripts in salivary extracellular vesicle cargo isolated from aged populations
Wen, S., Chang, Y., Kelsey, M. M. G., Pereira, M., Alaimo, H., Teixeira, E. M., Pracht, J. R., Daiello, L. A., Drake, J. D., Sedivy, J. M., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2025.1707720 · Cited by 3
Exercise-derived extracellular vesicles in oncology: a new frontier for translational nanomedicine
Silvestri, M., Fantini, C., Duranti, G., Grazioli, E., Caporossi, D., Balbi, C., & Dimauro, I. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07742-w · Cited by 3
“This is typically challenging for synthetic nanoparticles or free drugs [46, 47].”
Metadata
- Authors
- Banks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L.
- Affiliations
- University of Washington (US)
- University of Pittsburgh (US)
- Corresponding author
- Banks, William A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-21
- Volume
- 21
- Issue
- 12
- Pages
- 4407
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352415
- OpenAlex
- W3036596408
- Cited by
- 561
- References
- 57
- Citations by year
- 2026: 99 · 2025: 102 · 2024: 132 · 2023: 90 · 2022: 81 · 2021: 54 · 2020: 2
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (1RO1 AG046619)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- extracellular vesicles, exosomes, blood-brain barrier, BBB crossing, brain pharmacokinetics, lipopolysaccharide, inflammation, mannose 6-phosphate receptor, CD46, integrins, ICAM-1, vesicular transporters
- MeSH terms
- Animals, Biological Transport, Blood-Brain Barrier, Cell Line, Humans, Inflammation, Male, Cell Line, Tumor, Mice, Exosomes, Transcytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.